Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Immune Tolerance Induction with Alphanate in Severe Congenital Hemophilia A with Inhibitors
2015-005524-26Phase 2Terminated
- Sponsor
- Grifols
- Start
- Jun 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of von Willebrand factor human in hemophilia A, sponsored by Grifols. Primary endpoint: Complete immune tolerance within 33 months. Started Jun 2016; status: terminated.
02
Drugs
von Willebrand factor human
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2015-005524-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005524-26.